Overview

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy recombinant human endostatin(endostar) durative transfusion combined with cocurrent chemoradiotherapy in advanced non-small cell lung cancer(NSCLC).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Affiliated Hospital of North Sichuan Medical College
Collaborator:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Treatments:
Cisplatin
Endostar protein
Endostatins
Etoposide